Berberine’s unique ability to sustain AMPK activity through proteasomal degradation of UHRF1 suggests a downstream epigenetic cascade that could explain its potent lipid‑lowering actions independent of PCSK9 inhibition. We hypothesize that berberine‑induced loss of UHRF1 reduces DNMT1‑mediated DNA methylation at the promoter of the farnesoid X receptor (FXR) gene, leading to increased FXR transcription. Elevated FXR activation then suppresses PCSK9 transcription via a SHP‑dependent mechanism, resulting in enhanced hepatic LDL‑receptor recycling and lowered circulating LDL‑C. This model extends the known lysosomal AMPK–AXIN1 pathway by linking UHRF1 turnover to chromatin remodeling and nuclear receptor signaling, offering a mechanistic bridge between berberine’s metabolic and lipid‑lowering effects. Importantly, the effect should be observable at the low micromolar concentrations (0.1–2.5 μM) that activate lysosomal AMPK without altering bulk AMP/ATP ratios, and it should be absent in cells where UHRF1 is constitutively overexpressed or FXR is pharmacologically blocked.

Testable Predictions

1. Molecular: In hepatocytes treated with berberine (0.5 μM), UHRF1 protein levels will decline within 6 h, accompanied by reduced DNMT1 activity and hypomethylation of CpG islands in the FXR promoter region.
2. Transcriptional: FXR mRNA and protein will increase proportionally to UHRF1 loss, and chromatin immunoprecipitation will show decreased methyl‑CpG binding protein 2 (MeCP2) occupancy at the FXR promoter.
3. Functional: Elevated FXR activation will lead to increased SHP expression and reduced PCSK9 mRNA secretion; LDL‑C uptake assays will show heightened LDL‑receptor–mediated clearance.
4. Pharmacologic Rescue: Overexpression of a degradation‑resistant UHRF1 mutant or treatment with the proteasome inhibitor MG‑132 will abolish berberine‑mediated FXR up‑regulation and PCSK9 suppression. Conversely, FXR antagonism (e.g., glyburide) will block the PCSK9‑lowering effect despite UHRF1 degradation.
5. In Vivo: Mice fed a high‑fat diet and administered berberine (200 mg/kg/day) will exhibit reduced hepatic UHRF1, increased FXR activity, and lower plasma PCSK9 and LDL‑C; these changes will be absent in liver‑specific UHRF1 transgenic mice or FXR knockout mice.
6. Microbiome Independence: Germ‑free mice receiving berberine will still show the UHRF1‑FXR‑PCSK9 axis modulation, indicating that the hypothesis does not rely on gut‑microbiota metabolites (though microbiome effects may augment the response).

Experimental Approach

• Cell Culture: Use human HepG2 and primary mouse hepatocytes. Treat with berberine (0.1–2.5 μM) ± MG‑132, UHRF1 overexpression plasmid, or siRNA. Measure UHRF1, DNMT1 activity (ELISA), FXR promoter methylation (bisulfite sequencing), FXR/SHP/PCSK9 expression (qPCR, Western blot), and secreted PCSK9 (ELISA).
• Reporter Assays: Clone the FXR promoter upstream of luciferase; test activity with berberine ± UHRF1 manipulation. Include mutant CpG sites to confirm methylation dependence.
• Animal Studies: C57BL/6J mice on HFD ± berberine for 8 weeks. Liver harvested for UHRF1, FXR, PCSK9; plasma lipids measured. Parallel groups: liver‑specific UHRF1‑OE and FXR‑KO via AAV‑CRISPR.
• Microbiome Control: Conduct parallel experiments in germ‑free mice to isolate host‑cell effects.

Falsifiability

If berberine fails to reduce UHRF1 or if UHRF1 degradation does not correlate with FXR promoter hypomethylation and subsequent PCSK9 suppression across the specified conditions, the hypothesis is refuted. Likewise, if pharmacological blockade of FXR does not rescue PCSK9 expression despite confirmed UHRF1 loss, the proposed epigenetic‑nuclear receptor link is invalid.

Broader Implications

Confirming this pathway would position berberine as a dual‑acting agent that not only activates lysosomal AMPK but also rewires epigenetic regulation of bile‑acid signaling to improve lipid homeostasis. It would also provide a mechanistic rationale for combining berberine with existing FXR agonists or PCSK9 inhibitors in atherosclerotic disease, and it highlights UHRF1 as a novel druggable node for metabolic syndrome therapeutics.